期刊
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
卷 116, 期 -, 页码 167-173出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2021.12.343
关键词
Hydroxychloroquine; COVID-19; Chemoprophylaxis; Randomized trial; Health care workers
资金
- Henry Ford Health System
- Bill and Melinda Gates Foundation [INV-018560]
- Bill and Melinda Gates Foundation [INV-018560] Funding Source: Bill and Melinda Gates Foundation
This study demonstrated the safety of using HCQ for chemoprophylaxis against COVID-19 in high-risk populations through a randomized placebo-controlled trial, with no hospitalizations or interventions required for participants.
Background: Health care workers (HCW) are among the highest risk groups for acquisition of COVID-19 because of occupational exposures. The WHIP COVID-19 Study aimed to evaluate the safety and efficacy of hydroxychloroquine (HCQ) as chemoprophylaxis for SARS-CoV-2 infection in this population. Methods: HCW, first responders, and other occupationally high-risk participants were enrolled in a ran-domized, placebo-controlled clinical study of HCQ from April to October 2020. The trial compared daily versus weekly HCQ with placebo and with a prospective cohort on HCQ for autoimmune diseases. Par-ticipants were followed for 8 weeks. Serology or a positive polymerase chain reaction test was used to determine laboratory confirmed clinical cases. Results: A total of 624 participants were randomized to placebo (n = 200), weekly HCQ (n = 201), daily HCQ (n = 197). For the primary safety end point, 279 (4 4.7%) participants experienced adverse event (AE) level II or lower (total AEs n = 589), similar rates in all randomized groups (P = .188) with no hospital-izations or interventions required. Only 4 laboratory confirmed COVID-19 cases occurred, with 2 in the placebo arm and one in each HCQ randomized arm. Conclusions: This randomized placebo-controlled trial was able to demonstrate the safety of HCQ out -patient chemoprophylaxis in high-risk groups against COVID-19. Future studies of chemoprophylaxis for SARS-CoV-2 are needed as the epidemic continues worldwide. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据